article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Patients who transitioned to the oral daily formulation after a lengthy treatment with the weekly IV formulation improved further in this assessment of exercise tolerance, which is the primary endpoint of the ongoing Phase 3 LEVEL study. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Potassium Nitrate in Heart Failure With Preserved Ejection Fraction

JAMA Cardiology

This study assesses the impact of chronic inorganic nitrate administration on exercise tolerance in a larger trial of participants with heart failure with preserved ejection fraction.

article thumbnail

Toward a New SUMMIT in Heart Failure with Preserved Ejection Fraction

The New England Journal of Medicine

Treatment options for heart failure with preserved ejection fraction have historically been limited. In a 2016 review of this condition in the Journal, treatment recommendations focused on diuretics, exercise training, and management of coexisting conditions.1

article thumbnail

Evaluation of the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction

American College of Cardiology

The goal of the CAMEO-DAPA trial was to assess whether dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), affects rest and exercise pulmonary capillary wedge pressure (PCWP) in patients with heart failure with preserved ejection fraction (HFpEF).

article thumbnail

Diastolic exercise stress testing in heart failure with preserved ejection fraction: The DEST?HF study

European Journal of Heart Failure

ΔPAWP: difference of PAWP between rest and peak exercise. 2–4 points denotes an intermediate risk for heart failure with preserved ejection fraction (HFpEF) at non-invasive testing at rest. 2–4 points denotes an intermediate risk for heart failure with preserved ejection fraction (HFpEF) at non-invasive testing at rest.

article thumbnail

Cardiopulmonary exercise testing in Fabry disease: is it an early marker of cardiomyopathy?

Heart BMJ

Cardiomyopathy is a primary determinant of prognosis in FD and typically presents as a heart failure (HF) with a preserved ejection fraction phenotype. Cardiomyopathy is a primary determinant of prognosis in FD and typically presents as a heart failure (HF) with a preserved ejection fraction phenotype.

article thumbnail

Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure With Preserved Ejection Fraction in the Ambulatory Outpatient Setting

Circulation

Use of separate rule-in and rule-out diagnostic thresholds stratified by BMI reduces miscategorization and can guide more appropriate use of exercise testing for possible HFpEF. In our study, NT-proBNP provided little value in those with AF and dyspnea because the presence of AF is by itself a robust biomarker of HFpEF.